Key Takeaways
- • Alkemi Growth Capital plans to launch its third fund targeting $125-150 million between March and June 2027, according to founding partner Alka Goel in an interview with Business Standard.
- • The proposed fund follows first and second funds of $40 million and $75 million; the $75 million fund has so far backed 14 companies.
- • Alkemi has begun informal conversations with existing limited partners, while formal fundraising has not yet started.
- • The firm plans to increase deep-tech exposure and raise its average ticket size to ₹25-40 crore, up from an initial ₹20-30 crore range.
- • Existing LPs include the International Finance Corporation (IFC), the Teachers' Retirement System of the State of Illinois (TRS), and the Small Industries Development Bank of India (Sidbi).
Summary
Alkemi has begun informal discussions with existing limited partners, though formal fundraising has not yet begun. The firm has previously raised capital from the International Finance Corporation (IFC), the Teachers' Retirement System of the State of Illinois (TRS), and the Small Industries Development Bank of India (Sidbi). Through its ongoing $75 million fund, Alkemi has invested in 14 companies and expects to back four more over the next six months. The firm typically invests in four to six companies annually, with initial cheque sizes of ₹20-30 crore.
The third fund is intended to expand the firm's exposure to healthcare deep-tech. Goel said Alkemi has already invested in two or three deep-tech companies over the past one and a half years and expects to do more. The average ticket size is likely to rise to ₹25-40 crore. Portfolio companies cited include Redcliffe Labs (diagnostics), Medvital (medical devices), Datar Cancer Genetics (IVD deep-tech), Medulance (emergency medical response), Alphadroid (autonomous mobility robots), Leumas (physical AI for pharma manufacturing), and Jagruti (mental health and rehabilitation).
Preventive healthcare is another core theme. Goel attributed growing spending on preventive wellness, diagnostics, wearables, nutrition and fitness to rising disposable incomes and greater consumer awareness, and said the opportunity extends beyond hospitals to pharmaceuticals, medical devices, diagnostics and preventive health. In her words, "Healthcare is forever. There is no limit to innovation in healthcare."
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.